Format

Send to

Choose Destination
Lung Cancer. 2011 Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011.

Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.

Author information

1
Baskent University, School of Medicine, Dept. of Medical Oncology, Adana, Turkey. doctorhope@gmail.com

Abstract

Advanced thymic carcinoma (TC) is a very aggressive disease. To date there are no established treatment options for the refractory and recurrent disease and only a few prospective trials have been conducted in patients with TC. Here we present a case of a relapsed TC patient, who, by using combination chemotherapy, showed a positive response to sorafenib with C-KIT exon 11 mutation.

PMID:
20970876
DOI:
10.1016/j.lungcan.2010.09.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center